Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Infection

Syphilis on the rise — a need for alternative therapies and vaccines

Nature Reviews Urology volume 21, page 457 (2024)Cite this article

Subjects

Syphilis, caused by the bacterium Treponema pallidum subsp. pallidum (TPA), re-emerged as a global health problem in the twenty-first century, with a drastic increase in syphilis diagnoses reported in the past 20 years. Injection with the long-acting benzathine penicillin G is the gold-standard treatment for syphilis, but the increased number of patients combined with a limited supply chain capacity led to a global benzathine penicillin shortage. Thus, alternative therapies and vaccine development are absolute priorities in the field and have been discussed in two studies published in The New England Journal of Medicine and The Journal of Infection Diseases, respectively.

The first article is a correspondence in which the authors evaluated the current prevalence of azithromycin resistance to assess whether this macrolide antibiotic (which current Centers for Disease Control and Prevention and Canadian guidelines suggest not to use) could be included in the discussion about alternative syphilis therapies in the context of benzathine penicillin shortage. A total of 604 TPA strains were sampled between 2017 and 2023 across 13 US states, Washington DC and two Canadian states, and azithromycin resistance was assessed through the presence of A2058G or A2059G mutations in the 23S ribosomal RNA subunit gene, which both confer resistance to azithromycin. Overall, 99.2% of sampled strains (599 of 604) were genotypically resistant to azithromycin, with 584 (97.5%) and 15 (2.5%) strains carrying the A2058G and the A2059G mutations, respectively. Azithromycin resistance also drastically increased (99.3%) in women and in men who have sex with women, who historically experienced low resistance (14%, according to data obtained between 2007 and 2009). Patients in this study were shown to be representative of patients with syphilis in North America. Overall, the authors concluded that these data do not support the use of azithromycin, and clinicians should consider alternative solutions (doxycycline or ceftriaxone) in non-pregnant patients in the context of benzathine penicillin G shortage.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original articles

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Urology http://www.nature.com/nrurol/

    Maria Chiara Masone

Authors
  1. Maria Chiara Masone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Chiara Masone.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Masone, M.C. Syphilis on the rise — a need for alternative therapies and vaccines. Nat Rev Urol 21, 457 (2024). https://doi.org/10.1038/s41585-024-00916-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-024-00916-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing